GenomeRx, LLC is an early-stage biotechnology company dedicated to building a modern siRNA therapeutics engine—one that combines rigorous science, thoughtful design, and a commitment to global access.
GENOMERX, LLC – Next-Generation Precision RNAi Therapeutics targeting genetically validated drivers across
CNS, retina, and liver metabolic/cardiometabolic diseases
To develop best-in-class siRNA therapeutics that silence disease-causing genes with high potency, durability, and safety – addressing significant unmet needs in Parkinson’s disease (CNS), dry AMD, and liver metabolic/cardiometabolic diseases.
We start with strong human biology and genetics, then design programs that are mechanistically grounded and clinically meaningful.
Each new program is chosen not only for its therapeutic promise, but also for what it teaches us about siRNA design, delivery, and translation across indications.
GenomeRx is built to take advantage of a distributed model—leveraging best-in-class partners for specialized functions while maintaining a lean internal core focused on design, data, and strategy.
A RNA therapeutics, leading strategic direction and partnerships.
Experts in RNA chemistry, liver disease, nephrology, and translational pharmacology.
Seasoned industry leaders guiding clinical development, regulatory strategy, and global market access.
Decisions are grounded in data, reproducible experiments, and honest interpretation.
We design processes to move quickly without cutting scientific or ethical corners.
With our partners and stakeholders, we’re clear about risk, timelines, and what we know—or don’t yet know
From early on, we consider manufacturing, cost, and distribution challenges that influence who can ultimately receive the medicines we develop.
GenomeRx seeks collaborations across the drug development continuum, including:
We engage flexibly—through research collaborations, option-to-license agreements, or joint development structures—based on the needs of each program.